Earth Science Tech, Inc.
ETSTOTCHealthcare · Pharmaceutical Preparations · FL · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $33.1M | $12.0M | $48,537 | $14,123 | $140,902 | $526,139 |
| Operating income | — | $892,349 | −$936,683 | −$226,706 | −$4.3M | −$908,567 |
| Net income | $3.3M | $812,139 | −$365,405 | $3.2M | −$4.4M | −$1.2M |
| Total assets | $7.1M | $3.9M | $2.7M | $76,942 | $64,564 | $154,552 |
| Total liabilities | $3.2M | $1.6M | $1.6M | $1.9M | $5.1M | $980,351 |
| Equity | $3.9M | $2.2M | $1.1M | −$1.8M | −$5.0M | −$825,799 |
| EPS (diluted) | $0.01 | $0.00 | $-0.00 | $0.06 | $-0.08 | — |
| Shares out. | 294.3M | 310.0M | 282.6M | 54.2M | 53.2M | 40.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- 9.8%
- Return on equity
- 84.5%
- Return on assets
- 46.0%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 45.5%
- Debt / equity
- 0.83×
- Book value / share
- $0.01
- Revenue growth (YoY)
- 177.1%
- Net income growth (YoY)
- 300.6%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Accruals / assets
- −15.8%clean
- Beneish M-Score
- -3.51normal
- Piotroski F-Score
- 7/8strong
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 5 good- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Jun 28, 2024
- NT 10-Qmissed a reporting deadline ↗Feb 14, 2024
- NT 10-Kmissed a reporting deadline ↗Jun 28, 2022
- NT 10-Qmissed a reporting deadline ↗Feb 14, 2022
- NT 10-Qmissed a reporting deadline ↗Nov 16, 2021
- NT 10-Qmissed a reporting deadline ↗Aug 17, 2021
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Saumat Giorgio R.Officer — CEO | Jul 22, 2025 | Buy | 50,000 | $0.20 |
| Saumat Giorgio R.Officer — CEO | Jul 21, 2025 | Buy | 100,000 | $0.20 |
| Sanchez Yovan ArturoDirector | Jul 8, 2025 | Buy | 11,105 | $0.18 |
| Sanchez Yovan ArturoDirector | Jul 2, 2025 | Buy | 60,805 | $0.20 |
| Sanchez Yovan ArturoDirector | Mar 14, 2025 | Buy | 100,000 | $0.12 |
| Tabraue Mario GuillermoOfficer — COO | Mar 10, 2025 | Buy | 40,000 | $0.14 |
| Rose Christopher AlanOfficer — CTO | Mar 4, 2025 | Buy | 10,500 | $0.15 |
| Saumat Giorgio R.Officer — CEO | Feb 24, 2025 | Buy | 100,000 | $0.18 |
| Sanchez Yovan ArturoDirector | Jan 31, 2025 | Buy | 100,000 | $0.18 |
| Flores Ernesto LOfficer — CFO | Jan 28, 2025 | Buy | 43,478 | $0.23 |
| Tabraue Mario GuillermoOfficer — COO | Jan 24, 2025 | Buy | 20,000 | $0.23 |
| Saumat Giorgio R.Officer — CEO | Dec 27, 2024 | Buy | 600 | $0.14 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 101,455 | 1.0 | +432.6% |
| Apr 30, 2026 | 19,050 | 1.0 | +169.1% |
| Apr 15, 2026 | 7,078 | 1.0 | +487.9% |
| Mar 31, 2026 | 1,204 | 1.0 | +100.0% |
| Feb 13, 2026 | 695 | 1.0 | -58.6% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Amended charter or bylawsApr 17, 2026
- Regulation FD disclosureMar 24, 2026
- Director / officer changeMar 13, 2026
- Changed auditor · Regulation FD disclosureFeb 20, 2026
- Director / officer change · Regulation FD disclosureFeb 17, 2026
- Other material eventJan 6, 2026
- Other material eventJan 5, 2026
- Regulation FD disclosureNov 12, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.